Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Immunothrombolysis: deCoding neutrophiL Engagement in Active thrombus Resolution

Ziel

Thrombosis remains a leading global cause of morbidity and mortality. In this process inflammation has been recognised as central driver besides platelets and coagulation. My work and that of others has defined thromboinflammation, the paradigm in which neutrophil–coagulation crosstalk drives vascular occlusions in the microvasculature and macrovasculature.

Recently, I introduced a previously unrecognized and paradigm-shifting concept: Neutrophils do not cease to act once a thrombus is formed. Instead, they continuously infiltrate established clots and acquire thrombolytic properties, directly promoting thrombus-resolution. I have termed this novel process immunothrombolysis, representing the conceptual opposite to thromboinflammation. A neutrophil-driven program of endogenous thrombus-clearance challenges one of the most entrenched assumptions in vascular biology. This has profound implications: If the underlying cellular, molecular and temporal mechanisms of immunothrombolysis can be harnessed, the immune-balance could artificially be tipped early towards endogenous thrombus resolution.
I hypothesize that neutrophil–coagulation interplay exerts stage-dependent, temporo-dynamically opposing effects, culminating in immunothrombolysis. To establish this new principle, I will:
1) Map the spatio-temporo-dynamic trajectories of continuous neutrophil infiltration, identifying the time and site where the switch from thromboinflammation to immunothrombolysis
2) Define the molecular triggers that reprogram neutrophils into a thrombolytic phenotype driving immunothrombolysis in the macrovasculature
3) Identify the molecular switches that induce endogenous microvascular thrombo-resolution to allow microvascular recanalyzation

This project could redefine thrombosis biology and pioneer endogenous immune-modulation for thrombus resolution, thereby reducing systemic therapeutic bleeding risks.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC - HORIZON ERC Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-STG

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Netto-EU-Beitrag
€ 0,00
Adresse
GESCHWISTER SCHOLL PLATZ 1
80539 Planegg
Deutschland
Region
Bayern Oberbayern München, Kreisfreie Stadt
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 1 499 837,00

Begünstigte (2)